851 reports of this reaction
1.9% of all BIMATOPROST reports
#9 most reported adverse reaction
HYPERSENSITIVITY is the #9 most commonly reported adverse reaction for BIMATOPROST, manufactured by Allergan, Inc.. There are 851 FDA adverse event reports linking BIMATOPROST to HYPERSENSITIVITY. This represents approximately 1.9% of all 44,865 adverse event reports for this drug.
Patients taking BIMATOPROST who experience hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERSENSITIVITY is a less commonly reported adverse event for BIMATOPROST, but still significant enough to appear in the safety profile.
In addition to hypersensitivity, the following adverse reactions have been reported for BIMATOPROST:
The following drugs have also been linked to hypersensitivity in FDA adverse event reports:
HYPERSENSITIVITY has been reported as an adverse event in 851 FDA reports for BIMATOPROST. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERSENSITIVITY accounts for approximately 1.9% of all adverse event reports for BIMATOPROST, making it a notable side effect.
If you experience hypersensitivity while taking BIMATOPROST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.